Key facts: American Well Targets Rise; Hold Consensus, 2% Upside

Analysts at TD Cowen and Stifel maintained Hold ratings on American Well (AMWL) but raised their price targets to $13 and $12, respectively. The average 12-month price target increased to $13, suggesting 2% upside from the Nov. 3 close. The consensus remains Hold with one Buy, seven Holds, and no Sells.

Original reporting
Published Nov 5, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: American Well Targets Rise; Hold Consensus, 2% Upside — source image
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

Target upgrades can attract short-term buying interest, but the modest 2% upside limits large moves.

02

Market read

Small but fresh analyst upgrades for AMWL provide a modest trading cue.

03

What to watch

Potential regulatory changes and reimbursement uncertainties could limit upside.

Relevance 6/10Novelty 5/10Timing: pre-market

Background

Analyst firms periodically update price targets based on earnings, guidance, and market conditions.

Company-level read

Ticker impact

$AMWLBullishHigh confidence
Context

TD Cowen and Stifel raised AMWL price targets to $13 and $12 respectively, implying ~2% upside.

Expected impact

likely slight upward pressure as investors price in the new targets

Evidence & confidence

Target raises are fresh and directly indicate a bullish view, but the magnitude is small.

Market effects

Minor positive signal for the telehealth sector as analysts see modest upside.

US market focus; limited broader regional effect.

Low global relevance; impact confined to AMWL and its peers.

Counterpoint

The target increase may be premature given competitive pressures in telehealth.

Key entities

  • TD Cowen

    Raised AMWL price target to $13.

  • Stifel

    Raised AMWL price target to $12.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.